N-[(2-bromophenyl)(phenyl)methyl]urea | 117211-22-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2-bromophenyl)(phenyl)methyl]urea
• 英文别名: o-bromobenzhydrylurea；[(2-Bromophenyl)-phenylmethyl]urea
• CAS: 117211-22-0
• 化学式: C₁₄H₁₃BrN₂O
• 分子量: 305.174
• InChiKey: QDJBQPCSNUHGFA-UHFFFAOYSA-N

物化性质

• 沸点：
  440.5±45.0 °C(Predicted)
• 密度：
  1.440±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-[(2-bromophenyl)(phenyl)methyl]urea 以97%的产率得到N,N'-Bis((2-bromophenyl)phenylmethyl)urea
  参考文献：
  名称：

  Synthetic anticonvulsants, antihypoxics, and liver monooxygenase system inducers based on amides and urea. V. Synthesis and anticonvulsive and antihypoxic activities of 1,3 dibenzhydrylureas

  摘要：

  DOI：

  10.1007/bf00810976
• 作为产物：
  描述：

  alpha-(2-溴苯基)苄胺 、 尿素 在 盐酸 作用下， 反应 3.0h， 以62%的产率得到N-[(2-bromophenyl)(phenyl)methyl]urea
  参考文献：
  名称：

  Quantitative relationship between anticonvulsant activity in N-benzhydrylamides and N-benzhydrylureas, their structures, and13c NMR spectra

  摘要：

  DOI：

  10.1007/bf00769646

文献信息

• DRUGS TO PREVENT HPV INFECTION
  申请人：Lambert Paul F.

  公开号：US20110165220A1

  公开（公告）日：2011-07-07

  A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.
• US9066951B2
  申请人：——

  公开号：US9066951B2

  公开（公告）日：2015-06-30
• US9949980B2
  申请人：——

  公开号：US9949980B2

  公开（公告）日：2018-04-24
• [EN] DRUGS TO PREVENT HPV INFECTION<br/>[FR] MÉDICAMENTS POUR PRÉVENIR UNE INFECTION PAR PAPILLOMAVIRUS
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2009148961A2

  公开（公告）日：2009-12-10

  A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.